DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-023/S-025

Falcon Pharmaceuticals, Ltd.
Alcon Research, Ltd.
Attention: Norma J. Schafer, M.S.
Manager, Regulatory Affairs
6201 South Freeway, R7-16
Fort Worth, TX 76134-2099

Dear Ms. Schafer:

Please refer to your supplemental new drug application dated August 19, 2004, received August 20, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Maxitrol (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension). This application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA modernization Act of 1997.

We acknowledge receipt of your submission dated November 26, 2007. This submission constituted a complete response to our November 8, 2007, action letter.

This "Changes Being Effected" supplemental new drug application provides for the addition of a **Geriatric Use** subsection to the label.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text listed below.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the enclosed labeling text for the package insert submitted November 26, 2007. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 50-023/S-025."

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
Rockwall II, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Raphael R. Rodriguez, Regulatory Project Manager, at (301) 796-0798.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, M.D.
Acting Director
Division of Anti-Infective and
Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Wiley Chambers

4/24/2008 10:49:28 AM